Randomized Clinical Trial of Anesthetic Efficacy of Buffered Versus Conventional Local Anesthetic Agent in Patient with Symptomatic Irreversible Pulpitis

Srujana Hemmanur

Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.

Iffat Nasim *

Department of Conservative Dentistry and Endodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.

*Author to whom correspondence should be addressed.


Abstract

Local anesthetics are used to alleviate pain and discomfort of the patient during root canal therapy. Effective pain control is an absolute essential for better patient compliance and attitude towards the treatment. The purpose of the study was to observe the onset of action of local anesthesia, its duration of action and pain experienced by the patient during treatment procedure. Patients diagnosed with symptomatic irreversible pulpitis and no changes in the periapical tissues indicated for endodontic management were included in the study. The study was a double blinded randomised clinical trial. The non-randomization procedure allocated 32 teeth with symptomatic irreversible pulpitis, 8 teeth to each control group (group I treated by conventional 2% Lignocaine and group III treated by conventional 4% Articaine HCL) and 8 teeth to each experimental group (group II treated by buffered 2% Lignocaine and group IV treated by buffered 4% Articaine HCL).The buffering of local anesthetic agent improves the efficacy, onset of action and longevity of the local anesthetic agent. Buffered local anesthetics can be used in place of conventional local anesthetic agents. Long term clinical trials will be required to observe the result and to draw a comment and conclusion.

Keywords: Anesthetics, buffered, pain management


How to Cite

Hemmanur, S. and Nasim, I. (2020) “Randomized Clinical Trial of Anesthetic Efficacy of Buffered Versus Conventional Local Anesthetic Agent in Patient with Symptomatic Irreversible Pulpitis”, Journal of Pharmaceutical Research International, 32(17), pp. 1–10. doi: 10.9734/jpri/2020/v32i1730662.